选择性RET激酶抑制用于RET变异癌症患者
LOXO-292是一种选择性RET抑制剂,临床前研究显示其具有强效抗RET活性、高选择性及中枢神经系统覆盖。两例RET变异且多激酶抑制剂耐药的癌症患者接受LOXO-292治疗,通过实时药代动力学指导快速剂量滴定,均获得确认的肿瘤缓解。
要点
- LOXO-292在临床前多种RET依赖模型中显示强效选择性抗RET活性。
- 两例多激酶抑制剂经治的RET变异患者接受LOXO-292后均获确认缓解。
- 一例甲状腺髓样癌肝转移患者肿瘤标志物快速下降且症状缓解。
核心结论
- 结果证实RET变异具有临床可操作性,LOXO-292对多激酶抑制剂经治的RET变异肿瘤有 promising 疗效。
研究设计与样本
- 临床前研究使用多种体外和体内RET依赖肿瘤模型确认LOXO-292的抗RET活性、选择性及中枢神经系统覆盖。
- 因临床紧急需求,两例RET变异且多激酶抑制剂耐药的患者接受LOXO-292治疗,采用实时药代动力学指导的快速剂量滴定。
主要发现
- 临床前,LOXO-292对携带内源性RET基因变异的人癌细胞系、表达KIF5B-RET融合蛋白(±RET V804M门控耐药突变或常见RET激活突变M918T)的工程细胞、以及RET变异人癌细胞系和患者来源异种移植瘤(包括脑内原位注射的RET融合阳性患者来源异种移植瘤)显示强效选择性抗RET活性。
- 一例RET M918T突变甲状腺髓样癌肝转移且获得性RET V804M门控耐药突变、既往接受过六种MKI方案的患者,经LOXO-292治疗后肿瘤降钙素、CEA和游离DNA快速下降,疼痛性肝肿大和肿瘤相关腹泻缓解,并获确认的肿瘤缓解。
- 一例KIF5B-RET融合阳性肺癌、对阿来替尼获得性耐药且有症状性脑转移的患者,经LOXO-292治疗后脑部病灶显著缓解,症状消失。
临床怎么用
- 对于多激酶抑制剂经治的RET变异肿瘤患者,可考虑使用选择性RET抑制剂LOXO-292。
- 治疗期间可利用实时药代动力学评估指导快速剂量滴定,以安全快速达到有效临床暴露。
局限性
- 本文仅报告两例患者,样本量极小,结果属概念验证性质。
- 临床前数据不能直接推断临床疗效,需更大规模临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with anti-RET activity in RET-altered patients appears limited, calling into question the therapeutic potential of targeting RET. LOXO-292 is a selective RET inhibitor designed to inhibit diverse RET fusions, activating mutations and acquired resistance mutations. PATIENTS AND METHODS: Potent anti-RET activity, high selectivity, and central nervous system coverage were confirmed preclinically using a variety of in vitro and in vivo RET-dependent tumor models. Due to clinical urgency, two patients with RET-altered, MKI-resistant cancers were treated with LOXO-292, utilizing rapid dose-titration guided by real-time pharmacokinetic assessments to achieve meaningful clinical exposures safely and rapidly. RESULTS: LOXO-292 demonstrated potent and selective anti-RET activity preclinically against human cancer cell lines harboring endogenous RET gene alterations; cells engineered to express a KIF5B-RET fusion protein -/+ the RET V804M gatekeeper resistance mutation or the common RET activating mutation M918T; and RET-altered human cancer cell line and patient-derived xenografts, including a patient-derived RET fusion-positive xenograft injected orthotopically into the brain. A patient with RET M918T-mutant medullary thyroid cancer metastatic to the liver and an acquired RET V804M gatekeeper resistance mutation, previously treated with six MKI regimens, experienced rapid reductions in tumor calcitonin, CEA and cell-free DNA, resolution of painful hepatomegaly and tumor-related diarrhea and a confirmed tumor response. A second patient with KIF5B-RET fusion-positive lung cancer, acquired resistance to alectinib and symptomatic brain metastases experienced a dramatic response in the brain, and her symptoms resolved. CONCLUSIONS: These results provide proof-of-concept of the clinical actionability of RET alterations, and identify selective RET inhibition by LOXO-292 as a promising treatment in heavily pretreated, multikinase inhibitor-experienced patients with diverse RET-altered tumors.
引用
- Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018. PMID: 29912274. doi:10.1093/annonc/mdy137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。